You just read:

BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

News provided by

BioMarin Pharmaceutical Inc.

May 28, 2019, 06:50 ET